Effect of On-Admission Antiplatelet Treatment on Patients with Cerebral Hemorrhage
Authors:
- Valeria CasoVCValeria Caso
- Maurizio PaciaroniMPMaurizio Paciaroni
- Michele VentiMVMichele Venti
- Andrea AlbertiAAAndrea Alberti
- Francesco PalmeriniFPFrancesco Palmerini
- Paolo MiliaPMPaolo Milia
- Antonia M.R. BilleciABAntonia M.R. Billeci
- Giorgio SilvestrelliGSGiorgio Silvestrelli
- Sergio BiaginiSBSergio Biagini
- Giancarlo AgnelliGAGiancarlo Agnelli
- 28 June 2007
- journal article
- research article
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 24 (2-3) , 215-218
Abstract
Background: Antiplatelet treatment remains the first choice for primary and secondary prevention of vascular diseases; even so, expected benefits may be offset by risk of bleeding, particularly cerebral hemorrhage. The aim of this study was to assess the influence of antiplatelet treatment on clinical outcome at hospital discharge. Materials and Methods: Consecutive patients with first-ever stroke due to a primary intraparenchymal hemorrhage were prospectively identified over a 4-year period (2000–2003). Data on hemorrhage location, vascular risk factors, and antiplatelet and anticoagulant treatment were collected. At discharge, outcome was measured using the modified Rankin Scale (disabling stroke ≧3). Patients treated with anticoagulant therapy were excluded from the study. Results: Of 457 consecutive patients with cerebral hemorrhage, 94 (20.5%) had been taking antiplatelet agents. The treated patients (mean age for antiplatelet group 78.9 ± 9.0 years) were older than the nontreated patients (73.8 ± 9.4, p = 0.02). In-hospital mortality was 23.4 and 23.1% (p = n.s.) for patients who had been taking antiplatelet agents or no treatment. Poor outcome at discharge was found in 52.1 and 59.7% (p = n.s.), respectively. Univariate analysis showed that age and coma at admission were predictors of disability at discharge, but antiplatelet treatment was not. Additionally, age and coma were shown to be determinants of disability at discharge after multivariate analysis: OR 1.03 per year (95% CI: 1.018–1.049), p < 0.001 and OR 1.68 (95% CI: 1.138–2.503), p = 0.009, respectively. Conclusions: Hemorrhagic stroke continues to be responsible for a high percentage of disability and death. Furthermore, it was seen here that functional outcome was independent of previous antiplatelet treatment.Keywords
This publication has 21 references indexed in Scilit:
- Recombinant Activated Factor VII for Acute Intracerebral HemorrhageNew England Journal of Medicine, 2005
- Safety and Feasibility of Recombinant Factor VIIa for Acute Intracerebral HemorrhageStroke, 2005
- Transient Ischemic Attacks in Patients With Atrial FibrillationStroke, 2004
- European Stroke Initiative Recommendations for Stroke Management – Update 2003Cerebrovascular Diseases, 2003
- Use of the Original, Modified, or New Intracerebral Hemorrhage Score to Predict Mortality and Morbidity After Intracerebral HemorrhageStroke, 2003
- Stroke subtype and mortalitya follow-up study in 998 patients with a first cerebral infarctJournal of Clinical Epidemiology, 2003
- Aspirin and Risk of Hemorrhagic StrokeJAMA, 1998
- Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial FibrillationArchives of internal medicine (1960), 1994
- The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1990
- PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATIONThe Lancet, 1989